Ironwood Pharma (NASDAQ: IRWD) reported Q4 EPS of $0.36, $0.07 better than the analyst estimate of $0.29. Revenue for the quarter came in at $116.7 million versus the consensus estimate of $111.95 million.

GUIDANCE:

Ironwood Pharma sees FY2021 revenue of $370-385 million, versus the consensus of $427.5 million.

• U.S. LINZESS Net Sales Growth 3% to 5%
• Total Revenue $370 to $385 million
• Adjusted EBITDA1 >$190 million

For earnings history and earnings-related data on Ironwood Pharma (IRWD) click here.